Buprenorphine
BELBUCA, BRIXADI, Butrans, SUBLOCADE
Partial Opioid Agonist
NADAC/unit
$0.2942
No Shortage
Tier 1: 169.3%
PA Req: 191.8%
15 Manufacturers
39 ANDAs
Buprenorphine sublingual tablet is indicated for the treatment of opioid dependence and is preferred for induction.
vs. brand BELBUCA: Generic saves up to 97% per unit
Market Intelligence
2024-07-03 Class II Recall: Pfizer Inc.
2023-11-15 Class II Recall: PAR Sterile Products LLC
2023-06-14 Class II Recall: SUN PHARMACEUTICAL INDUSTRIES INC
Generic Manufacturers
ACTAVIS ELIZABETH LLCAMNEAL PHARMACEUTICALS LLCASCENT PHARMACEUTICALS INCBIODELIVERY SCIENCES INTERNATIONAL INCBRAEBURN INCDIFGEN PHARMACEUTICALS LLCETHYPHARM INCHIKMA PHARMACEUTICALS USA INCHOSPIRA INCINDIVIOR INCPH HEALTH LTDPURDUE PHARMA LPRHODES PHARMACEUTICALS LPRUBICON RESEARCH LTDSOMERSET THERAPEUTICS LLCSPECGX LLCSTRIDES PHARMA INTERNATIONAL AGSUN PHARMACEUTICAL INDUSTRIES LTDWATSON LABORATORIES INC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
Explore in the Ecosystem
Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.